Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022

6 May 2022
Leuven, Belgium, Boston, MA, US May 6, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, held its extraordinary and annual shareholders' meetings on May 3, 2022. The shareholders approved all items on the agenda of the annual shareholders' meeting. Concerning the extraordinary shareholders’ meeting, the attendance quorum required to deliberate and vote on the agenda items was not met, therefore, no vote was held. 

All documents pertaining to the extraordinary and annual shareholders’ meeting held on May 3, 2022, can be consulted on Oxurion’s website Oxurion/shareholders

Considering the foregoing, Oxurion announces and convenes a second extraordinary shareholders’ meeting that will be held on Tuesday, May 24, 2022, at 10:00 AM (CET), with the same agenda items as the extraordinary shareholders' meeting held on May 3, 2022, and for which no attendance quorum will apply to validly deliberate and vote. All documents relating to this second extraordinary general shareholders’ meeting can be consulted on Oxurion’s website Oxurion/shareholders